Target Pharma

VentureSouth portfolio news - January and early February 2018

2018 has started at a blistering pace. We were delighted to start the year with a good exit at FarmShots, but our portfolio companies continue to develop quickly. Updates include:

Portfolio news - November 2017

With a portfolio of 40 active companies, it can be hard to keep track of all their achievements. Our team of intrepid news searching scripts this month bring you:

Baebies: Completed its $10 million Series B raise, helped by a large strategic investment from BOE Technology Group.

Kwipped: Announced the completion of a further round of growth financing. We are pleased to be participating again, alongside the Wolfpack Investment Network.

Proterra:  In addition to providing the keynote content at the VentureSouth Summit, Proterra is sending buses to San Jose airport and Greensboro NC, and showing them off in Iowa, California and Shreveport. They're driving a market continuing to grow at 28% / year; Vox's recent industry review is a great primer.

Brightfield was featured in Motor Week for establishing more than 100 solar/EV charging stations across NC.

Reveal Mobile remains a "top 10 startup to watch." Learn more from Brian Handly in Forbes too.

And Target Pharma shared more of its plans for the rest of the year with the Triangle Business Journal.

Portfolio news - October 2017

In what is rapidly becoming the Proterra and Avadim show, below are links to some of the newsworthy items for late September and October.

Proterra: after several years and much effort, here come the first two Proterra buses in Greenville. And these are now officially world-record-breaking buses; take a seat Tesla.  And Proterra also announced partnerships with LG Chem, purchases by Van Hool, and more.

Avadim: Avadim announced a partnership with another market leader - this time Cardinal Health, to provide Avadim's line of topical bionome therapies. But not everything goes according to plan...

TiO Home announced a partnership with On Top Of The World Communities - a 3-year, 1,200-home program beginning in January.

Kwipped was featured in Total Station Markets, Chemistry World, MSN Lifestyle, the Journal Of Clinical Research Best Practices, and Irish Tech News - quite a selection. It also passed $75MM in listed assets.

Target Pharma: announced the extension of its partnerships with Bristol-Myers Squibb and Intercept, and a new partnership with Boehringer Ingelheim.

And Baebies announced a global distribution partnership for SEEKER with Trivitron's Labsystems Diagnostics.

Portfolio news - April 2017

Partnerships are crucial to early-stage companies to help them scale more rapidly. April saw the announcement of three example partnerships in our portfolio:

Other companies launched new products and hit milestones on their own:

And Proterra just keeps on rolling:

Portfolio news - November / December 2016

Several exciting updates from the last few weeks.

Proterra leads the way, with coverage in Forbes - and with press on three recent deals: (1) 15 new buses funded by the San Joaquin Valley Air Pollution Control District; (2) in the Chicago Tribune of an announcement in late October about a partnership with JLL to deliver 10 Catalyst buses for a service operating between Chicago’s commuter train stations the Prudential Plaza and Aon Center, both JLL-managed properties, in Chicago; and (3) the Pioneer Valley Transit Authority in Massachusetts.

Target Pharma continues to outperform, announcing its fourth disease community in partnership with Bristol-Myers Squibb - following its earlier announcement in partnership with Intercept Pharmaceuticals.

KIYATEC is not far behind - moving by popular acclaim from a startup to a breakout success. Keep up the good work.

Pharmright is accelerating nationally - demo'ing the Livi from Missouri to Maine.

Avadim announced its recognition by Vizient for the innovation of its technology and its plans to make $3.1 million of products per week at its new facility.

And lastly Crowdr provided a sneak peak of its mobile app Booster that launches in January. See you on there!

Portfolio news - October 2016

Each month we convey some of the achievements of some of our portfolio companies. There is plenty of good news already this month, so here is an early October portfolio update.

Avadim: Announced its plans for a $25 million investment to create 500 jobs in a new HQ in Western North Carolina. This helps to explain why early stage companies create all net new jobs.

Atlas Organics: delivered the goods - in the form of 20 tons of organic compost. Much more to come.

Pharmright: Announced a partnership with Med One to help finance purchases of the new Livi, and became a finalist in Med City News' patient engagement competition.

Target PharmaSolutions announced very exciting news about its first disease state communities and first industry partnerships.

And Baebies received unanimous approval from the FDA panel for its SEEKER screening.

Some really impressive milestones in several different areas. And on a lighter note, Growjourney helped Paul boast impressive rows of broccoli, kale, lettuce, chard, and bok choy in his vegetable garden for the first time. Baby kale pairs well with (VentureSouth sponsor) RJ Rockers' Bellringer. Who knew?

VentureSouth's latest investments - Crowdr and Target

VentureSouth is pleased to announce its latest investments. Thanks to the Moultrie News, Charleston RBJ, and others for helping to publicize the exciting news for Crowdr and Target Pharma.

For the record, VentureSouth didn't invest the $637,000 listed on Crunchbase, Target doesn't have $1.4 million left to raise, and the Palmetto Angel Fund didn't invest all the $250,000 in Crowdr. Crunchbase is good, but initial SEC Form D filings and crowd-sourced data do not always tell the full story on fundraising!

Still, these were material investments for VentureSouth, and we're delighted to be partnering with such impressive companies. We wish both the best of luck.

And a self-plug: learn more about angel investing in SC at one of our upcoming sessions on Crowdr.